Investing in AOA is investing in the future of women's healthcare.
Learn more about our current technologies as well as our future outlook below
A liquid biopsy diagnostic test that shows excellent results in the early diagnosis of ovarian cancer through analysis of tumor marker gangliosides.
For all general enquiries
For investor relations enquiries